Stock listing
KRX:007390 NATURECELL Co., Ltd. (네이처셀) 주가
Follow NATURECELL Co., Ltd. into a list and get an email when it puts out news.
Share price · KRX:007390
₩20,250 KRW -1,200 (-5.6%)
Close on Nov 20, 2026
- Day range
- ₩20,000 – ₩21,050 KRWNov 20, 2026
- Volume
- 228,450 sharesNov 20, 2026
- Market cap
- ₩1.07T KRWAt the close on Nov 20, 2026 · price × 53.08M shares outstanding
- 52-week range
- ₩16,550 – ₩36,950 KRWLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- ₩5.43B KRWMedian day 206,849 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · KRX:007390 · KRW, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| ₩20,250 | -1,200 | -5.6% | ₩20,950 | ₩21,050 | ₩20,000 | 228,450 | |
| ₩21,450 | -350 | -1.6% | ₩21,650 | ₩21,950 | ₩20,950 | 212,389 | |
| ₩21,800 | -150 | -0.7% | ₩21,550 | ₩22,500 | ₩21,550 | 193,982 | |
| ₩21,950 | +300 | +1.4% | ₩22,100 | ₩22,450 | ₩21,700 | 144,685 | |
| ₩21,650 | -450 | -2.0% | ₩21,800 | ₩22,750 | ₩21,600 | 206,186 | |
| ₩22,100 | -150 | -0.7% | ₩22,150 | ₩23,350 | ₩21,700 | 360,565 | |
| ₩22,250 | +1,700 | +8.3% | ₩21,500 | ₩22,950 | ₩21,300 | 295,200 | |
| ₩20,550 | -1,250 | -5.7% | ₩22,050 | ₩22,350 | ₩19,850 | 450,172 | |
| ₩21,800 | -100 | -0.5% | ₩21,650 | ₩22,600 | ₩21,650 | 194,529 | |
| ₩21,900 | -100 | -0.5% | ₩21,150 | ₩22,400 | ₩20,650 | 370,809 | |
| ₩22,000 | -450 | -2.0% | ₩22,700 | ₩23,100 | ₩21,700 | 230,587 | |
| ₩22,450 | +400 | +1.8% | ₩22,050 | ₩22,550 | ₩21,400 | 279,486 | |
| ₩22,050 | 0 | 0.0% | ₩21,850 | ₩22,950 | ₩21,750 | 177,234 | |
| ₩22,050 | +250 | +1.1% | ₩21,600 | ₩22,300 | ₩21,500 | 129,265 | |
| ₩21,800 | -400 | -1.8% | ₩21,600 | ₩22,200 | ₩21,550 | 115,644 | |
| ₩22,200 | +50 | +0.2% | ₩22,250 | ₩22,400 | ₩21,750 | 162,343 | |
| ₩22,150 | -150 | -0.7% | ₩22,300 | ₩22,800 | ₩21,950 | 148,956 | |
| ₩22,300 | +500 | +2.3% | ₩22,000 | ₩22,900 | ₩22,000 | 184,115 | |
| ₩21,800 | -1,350 | -5.8% | ₩23,000 | ₩23,000 | ₩21,450 | 217,247 | |
| ₩23,150 | -450 | -1.9% | ₩23,300 | ₩23,600 | ₩22,450 | 145,720 | |
| ₩23,600 | +750 | +3.3% | ₩22,750 | ₩23,900 | ₩22,200 | 230,125 | |
| ₩22,850 | -350 | -1.5% | ₩23,400 | ₩23,950 | ₩22,600 | 151,122 | |
| ₩23,200 | -650 | -2.7% | ₩23,650 | ₩23,850 | ₩22,900 | 231,782 | |
| ₩23,850 | +2,150 | +9.9% | ₩21,500 | ₩23,850 | ₩20,900 | 270,491 | |
| ₩21,700 | -450 | -2.0% | ₩21,800 | ₩22,200 | ₩20,250 | 324,829 | |
| ₩22,150 | -1,800 | -7.5% | ₩23,200 | ₩23,600 | ₩21,450 | 332,076 | |
| ₩23,950 | +550 | +2.4% | ₩23,250 | ₩24,300 | ₩23,050 | 194,349 | |
| ₩23,400 | -200 | -0.8% | ₩23,100 | ₩23,500 | ₩22,600 | 172,429 | |
| ₩23,600 | -950 | -3.9% | ₩24,550 | ₩24,750 | ₩23,550 | 203,632 | |
| ₩24,550 | -150 | -0.6% | ₩24,700 | ₩24,900 | ₩24,100 | 185,294 | |
| ₩24,700 | -50 | -0.2% | ₩24,850 | ₩25,200 | ₩24,500 | 110,688 | |
| ₩24,750 | 0 | 0.0% | ₩24,650 | ₩25,200 | ₩24,650 | 161,185 | |
| ₩24,750 | -350 | -1.4% | ₩25,350 | ₩25,800 | ₩24,600 | 191,512 | |
| ₩25,100 | +950 | +3.9% | ₩24,050 | ₩25,100 | ₩23,850 | 235,201 | |
| ₩24,150 | -200 | -0.8% | ₩24,250 | ₩24,650 | ₩24,050 | 141,960 | |
| ₩24,350 | -1,050 | -4.1% | ₩24,800 | ₩24,850 | ₩23,850 | 275,378 | |
| ₩25,400 | +750 | +3.0% | ₩24,750 | ₩25,800 | ₩24,750 | 271,616 | |
| ₩24,650 | -250 | -1.0% | ₩24,800 | ₩25,050 | ₩24,500 | 107,237 | |
| ₩24,900 | -100 | -0.4% | ₩25,050 | ₩25,250 | ₩24,750 | 115,822 | |
| ₩25,000 | +450 | +1.8% | ₩24,450 | ₩25,100 | ₩24,200 | 146,515 | |
| ₩24,550 | -50 | -0.2% | ₩24,750 | ₩24,900 | ₩24,550 | 125,250 | |
| ₩24,600 | -300 | -1.2% | ₩24,950 | ₩25,250 | ₩24,600 | 86,749 | |
| ₩24,900 | +50 | +0.2% | ₩24,700 | ₩24,950 | ₩24,500 | 111,119 | |
| ₩24,850 | -500 | -2.0% | ₩25,100 | ₩25,350 | ₩24,250 | 226,136 | |
| ₩25,350 | +250 | +1.0% | ₩25,050 | ₩25,500 | ₩24,950 | 178,199 | |
| ₩25,100 | -400 | -1.6% | ₩24,900 | ₩25,300 | ₩24,850 | 132,529 | |
| ₩25,500 | +700 | +2.8% | ₩24,600 | ₩25,500 | ₩24,500 | 275,355 | |
| ₩24,800 | +200 | +0.8% | ₩24,300 | ₩25,100 | ₩24,300 | 207,512 | |
| ₩24,600 | -100 | -0.4% | ₩24,300 | ₩25,450 | ₩24,300 | 195,576 | |
| ₩24,700 | +750 | +3.1% | ₩24,050 | ₩24,850 | ₩23,900 | 133,810 | |
| ₩23,950 | +50 | +0.2% | ₩24,550 | ₩24,800 | ₩23,950 | 165,655 | |
| ₩23,900 | +250 | +1.1% | ₩24,000 | ₩24,250 | ₩23,250 | 212,652 | |
| ₩23,650 | -2,150 | -8.3% | ₩25,150 | ₩25,250 | ₩23,600 | 323,893 | |
| ₩25,800 | -200 | -0.8% | ₩25,400 | ₩26,350 | ₩25,150 | 253,398 | |
| ₩26,000 | +750 | +3.0% | ₩24,850 | ₩26,250 | ₩24,450 | 322,329 | |
| ₩25,250 | -900 | -3.4% | ₩26,500 | ₩27,750 | ₩24,700 | 441,438 | |
| ₩26,150 | +1,700 | +7.0% | ₩23,950 | ₩28,000 | ₩23,650 | 621,692 | |
| ₩24,450 | -400 | -1.6% | ₩24,650 | ₩24,900 | ₩22,550 | 492,648 | |
| ₩24,850 | +1,250 | +5.3% | ₩23,300 | ₩24,950 | ₩22,800 | 336,625 | |
| ₩23,600 | -150 | -0.6% | ₩23,550 | ₩24,200 | ₩23,000 | 222,515 | |
| ₩23,750 | +350 | +1.5% | ₩22,950 | ₩24,050 | ₩22,650 | 349,400 | |
| ₩23,400 | +850 | +3.8% | ₩23,350 | ₩24,600 | ₩23,200 | 343,747 |
Splits
2 splits since 2008 · KRX:007390 · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 61-for-57 | Split | |
| 5-for-14 | Consolidation |
- Ticker
- KRX:007390
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- KRX
- Currency
- KRW
NATURECELL Co., Ltd. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
Valuation
EV/sales 51.4× against a median of 2.2×: the highest of 7 Biotechnology companies shown. Statements: 4 quarters to Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- ₩1.05T KRW
- P/E
- Loss
- EV/sales
- 51.4×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 17.1×
- Gross margin
- 49.3%
- Operating margin
- −17.9%
- Net margin
- −13.2%
- Debt to equity
- 0.0×
- Beta
- No index for this market yet
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| NATURECELL Co., Ltd. · KRX:007390 | US$803.4M | US$787.5M | n/a | 51.4× | n/a | 17.1× | −13.2% | 0.0× | n/a |
| Pharming Group NV · EURONEXT:PHARM | US$840.1M | US$766.3M | 34.4× | 2.0× | 19.8× | 2.9× | 6.3% | 0.4× | n/a |
| Corvus Pharmaceuticals, Inc. · NASDAQ:CRVS | US$815.7M | US$613.4M | n/a | n/a | n/a | 3.9× | n/a | 0.0× | 1.64 |
| Odyssey Therapeutics, Inc. · NASDAQ:ODTX | US$815.2M | US$512.7M | n/a | n/a | n/a | 2.2× | n/a | 0.1× | 1.11 |
| Arbutus Biopharma Corporation · NASDAQ:ABUS | US$796.4M | US$458.9M | 3.6× | 2.5× | 3.1× | 9.3× | 121.2% | 0.0× | 1.10 |
| Genfleet Therapeutics (Shanghai), Inc. Class H · HKEX:2595 | US$787.5M | US$519.4M | n/a | 26.6× | n/a | 3.3× | n/a | 0.0× | n/a |
| Shaanxi Micot Pharmaceutical Technology Co., Ltd. Class H · HKEX:2335 | US$778.7M | US$600.0M | n/a | n/a | n/a | 5.5× | n/a | 0.0× | n/a |
| Ironwood Pharmaceuticals, Inc. · NASDAQ:IRWD | US$778.1M | US$702.9M | 5.2× | 1.8× | n/a | n/a | 37.4% | n/a | 1.16 |
| Syndax Pharmaceuticals, Inc. · NASDAQ:SNDX | US$772.7M | US$695.6M | n/a | 2.4× | n/a | n/a | −72.4% | n/a | 0.64 |
| MeiraGTx Holdings plc · NASDAQ:MGTX | US$766.4M | US$715.6M | 9.8× | 1.8× | 3.7× | 3.6× | 19.5% | 0.6× | 1.57 |
| ORIC Pharmaceuticals, Inc. · NASDAQ:ORIC | US$764.9M | US$503.6M | n/a | n/a | n/a | 2.3× | n/a | 0.0× | 1.22 |
| Median of the others | US$783.1M | US$606.7M | 7.5× | 2.2× | 3.7× | 3.4× | 19.5% | 0.0× | 1.16 |
Team and board
| Director | Role |
|---|---|
| Jeong-Chan Ra | Chairman |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q4 2024 | Mar 28, 2025 · After close | +1.8% |
| Q3 2024 | Nov 9, 2024 · After close | +4.3% |
| Q2 2024 | Aug 9, 2024 · After close | −1.2% |
| Q1 2024 | May 14, 2024 · After close | +1.3% |
| Q4 2023 | Mar 21, 2024 · After close | +8.8% |
| Q3 2023 | Nov 14, 2023 · After close | +0.7% |
| Q3 2021 | Nov 12, 2021 | +4.2% |
| Quarter to Jun 30, 2021 | Aug 17, 2021 | +2.1% |
| Quarter to Mar 31, 2021 | May 14, 2021 | +30.3% |
Financials
Annual, in KRW
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 20.7B | 32.3B | 19.4B | 21.3B | 22.2B | 16.7B | 23.1B | 26.7B | 27.2B | 26.8B |
| Cost of revenue | 11.3B | 15.4B | 11.2B | 12.2B | 12.8B | 9.12B | 10.2B | 15.7B | 19.6B | 22.9B |
| Gross profit | 9.46B | 16.9B | 8.19B | 9.10B | 9.37B | 7.60B | 12.9B | 11.0B | 7.62B | 3.93B |
| Research and development | 64.4M | 338.9M | 2.22B | 1.58B | 1.42B | 1.69B | 150.3M | 30.9M | ||
| Selling, general and administrative | 6.86B | 14.6B | 15.1B | 15.7B | 16.1B | 11.5B | 8.77B | 8.15B | 6.12B | 7.53B |
| Operating income | -3.62B | 575.2M | -10.7B | -7.32B | -14.3B | -14.7B | 1.01B | 2.34B | -1.20B | -3.68B |
| Depreciation and amortization | 1.83B | 1.71B | 1.56B | 1.14B | 1.66B | 1.37B | 1.20B | 739.1M | 885.0M | 557.5M |
| EBITDA | -1.79B | 2.28B | -9.18B | -6.18B | -12.6B | -13.3B | 2.21B | 3.08B | -316.3M | -3.12B |
| Interest expense | 200.5M | 168.0M | 1.15B | 1.72B | 750.7M | 488.5M | 0 | 0 | 0 | 0 |
| Income before tax | -2.77B | 1.35B | -11.6B | -8.32B | -32.0B | -18.9B | 902.0M | 2.23B | -460.7M | -3.22B |
| Income tax | 0 | 0 | ||||||||
| Net income | -2.84B | 1.23B | -11.7B | -6.81B | -32.0B | -18.9B | 902.0M | 2.23B | -460.7M | -3.22B |
| Earnings per share, basic | -44.05 | 19.05 | -182.06 | -108.78 | -511.45 | -308.38 | 14.74 | 39.36 | -8.15 | -59.29 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 16.8B | 857.0K | 29.9B | 31.3B | 32.6B | 41.5B | 21.2B | 38.0K | 9.04B | 3.29B |
| Short-term investments | -320 | 200 | -440 | 0 | 7.00B | 25.0B | 300.0M | 10.0M | ||
| Receivables | 4.72B | 9.50B | 3.84B | 8.57B | 5.35B | 2.91B | 3.13B | 3.17B | 4.01B | 6.49B |
| Inventory | 5.89B | 2.97B | 3.21B | 3.05B | 3.15B | 3.15B | 3.14B | 3.20B | 4.72B | 5.66B |
| Current assets | 28.9B | 42.0B | 40.6B | 67.2B | 42.9B | 56.3B | 55.9B | 22.1B | 20.5B | 17.7B |
| Property, plant and equipment | 13.9B | 13.5B | 9.61B | 8.53B | 9.33B | 12.1B | 10.6B | 11.1B | 10.8B | |
| Goodwill | 976.0M | 976.0M | 976.0M | 976.0M | 1.03B | 976.0M | 976.0M | |||
| Total assets | 74.7B | 72.0B | 68.4B | 94.0B | 69.6B | 85.7B | 93.1B | 52.9B | 51.4B | 52.7B |
| Accounts payable | 1.20B | 1.96B | 297.9M | 1.07B | 1.75B | 359.1M | 1.06B | 1.41B | ||
| Current liabilities | 8.70B | 4.12B | 4.21B | 35.8B | 6.58B | 20.5B | 8.84B | 9.28B | 9.66B | 11.5B |
| Long-term debt | 0 | 0 | 0 | 23.0M | 69.0M | 1.87B | 6.24B | |||
| Total debt | 6.06B | 4.11B | 2.31B | 4.11B | 8.48B | |||||
| Total liabilities | 11.7B | 7.37B | 6.98B | 36.9B | 8.80B | 23.1B | 11.2B | 9.75B | 12.0B | 18.6B |
| Shareholders' equity | 63.0B | 64.6B | 61.4B | 57.2B | 60.8B | 62.7B | 81.9B | 43.1B | 39.5B | 34.0B |
| Shares outstanding | 64.4M | 64.4M | 64.2M | 62.6M | 62.6M | 61.2M | 61.2M | 56.8M | 56.5M | 54.4M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 156.7M | 1.51B | -2.13B | -14.9B | -10.1B | -5.41B | 357.5M | 3.70B | 5.29B | -2.14B |
| Capital spending | -16.6B | -3.12B | -6.12B | -3.80B | -455.4M | -2.72B | -1.42B | -413.7M | -631.9M | -2.00B |
| Free cash flow | -16.4B | -1.61B | -8.25B | -22.8B | -9.89B | -4.37B | -1.24B | 3.29B | 4.66B | -4.14B |
| Cash from investing | -3.66B | 15.6B | -15.3B | 4.82B | 15.5B | -30.7B | 1.55B | -1.06B | -4.88B | |
| Cash from financing | 190.1M | -14.9B | 29.1B | -3.71B | 10.3B | 36.6B | 398.3M | 1.57B | 4.79B | |
| Share buybacks | 1.23B | 16.0B | 10.7M | 1.76B | 37.9B | 444.3M | 1.61B | 189.0M | ||
| Change in cash | -11.6B | -1.52B | -1.36B | -1.29B | -8.95B | 20.3B | 6.36B | 5.82B | 5.60B | -2.20B |
Cap table
Built by 6ix from NATURECELL Co., Ltd.’s releases
- Common shares
- 53,076,400
- Fully diluted
- 53,076,400
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 53,076,400 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 53,076,400 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Jeong-Chan Ra | Chairman · Since at least Nov 5, 2026 |
Log in to ask 6ix AI your own questions about NATURECELL Co., Ltd.